SXLV:LSE:LSE-SPDR S&P U.S. Health Care Select Sector UCITS (USD)

ETF | Others |

Last Closing

USD 44.3625

Change

+0.40 (+0.90)%

Market Cap

USD 0.40B

Volume

7.70K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R15:LSE SoftBank Group Corp.

N/A

USD 9,217.80B
0R1E:LSE Nintendo Co. Ltd.

N/A

USD 7,596.04B
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

N/A

USD 618.20B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

N/A

USD 617.54B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

N/A

USD 617.54B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
XDJP:LSE Xtrackers Nikkei 225 UCITS ETF..

N/A

USD 348.03B
0QZK:LSE Coca-Cola Co.

N/A

USD 266.08B
0QZO:LSE 0QZO

N/A

USD 258.54B

ETFs Containing SXLV:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.15% 76% C+ 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.15% 75% C 73% C
Trailing 12 Months  
Capital Gain 17.23% 66% D+ 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.23% 65% D 68% D+
Trailing 5 Years  
Capital Gain 72.94% 82% B 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 72.94% 81% B- 82% B
Average Annual (5 Year Horizon)  
Capital Gain 11.42% 77% C+ 77% C+
Dividend Return 11.42% 77% C+ 77% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.69% 64% D 78% C+
Risk Adjusted Return 106.84% 99% N/A 99% N/A
Market Capitalization 0.40B 66% D+ 57% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike